breast cancer

[Cell Death & Disease] The authors showed that TRIM31 was downregulated in breast cancer tissues and negatively correlated with breast cancer progression. Both gain- and loss-of-function assays indicated that TRIM31 inhibited the proliferation, colony formation, migration, and invasion of breast cancer cells.

[Journal of Translational Medicine] Investigators evaluated FBXO43 expression in breast cancer (BC) and analyzed The Cancer Genome Atlas. RT-qPCR and western blotting were utilized to detect FBXO43 expression in BC cell lines.

[Cancer Cell International] Scientists systematically studied the role of FAM49B in the proliferation, metastasis, apoptosis, and chemoresistance of breast cancer, as well as the corresponding molecular mechanisms and downstream target.

[npj Breast Cancer] The authors present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations.

[British Journal of Cancer] The authors summarize the pre-clinical characterisation of ESR1 mutations and their association with clinical outcomes in metastatic breast cancer and primary disease.

[Rhizen Pharmaceuticals (BusinessNewsWire, Inc.)] Rhizen Pharmaceuticals AG announced that it has commenced dosing in a Phase II trial to evaluate Tenalisib in patients with locally advanced or metastatic breast cancer.